| It plans to phase out some products and enter into manufacture of new products. This is likely to take place in the second-half of the current financial year. |
| The company manufacturers diketene "� the basic unit for hundreds of derivatives in pesticides, chemicals, pharmaceuticals and dyestuffs "� and biotech products ephedrine and pseudoephedrine. |
| The infrastructure required to convert diketene into a derivative is minimal as every derivative is a single step reaction from diketene. Hence, the company has resilience to phase out the existing derivatives or introduce new ones as per the market demands. |
| Company sources told Business Standard that the company has entered into exclusive tie-ups with some pharmaceutical companies for intermediates, and is focusing upon the segment as a promising revenue stream in the future. |
| Following the timely onset of monsoons in the country, the company also expects its turnover to touch a mark of Rs 100 crore during the current financial year 2004-05. |
| In the diketene business, monsoons play a major role in the demand for agro-chemical and pharma intermediates. The company is to announce the results for the last financial year shortly. It earned a net profit of Rs 3.54 crore on a income of Rs 83.29 crore for the year ended March 31, 2003. |
| According to the sources, the company performed well on the exports front during the last financial year. |
| The exports were said to have touched around Rs 30 crore as compared to Rs 24 crore in the previous financial year 2002-03. The company is reportedly targeting 20 per cent growth in exports in the current fiscal 2004-05. |
| During the last fiscal, the company went for debt revamp and reduced interest costs. |
| During the year, the company succeeded in converting some high cost debt (long term loans and working capital) into low-cost foreign currency non-resident (FCNR) loans. Following this, the interest costs would come down by Rs 100-125 lakh, sources said. |
Top Section
Explore Business Standard